inmune bio inc - INMB
INMB
Close Chg Chg %
1.27 0.02 1.57%
Pre-Market
1.29
+0.02 (1.57%)
Volume: 368.56K
Last Updated:
Apr 8, 2026, 4:00 PM EDT
Company Overview: inmune bio inc - INMB
INMB Key Data
| Open $1.30 | Day Range 1.27 - 1.32 |
| 52 Week Range 1.09 - 11.64 | Market Cap $33.76M |
| Shares Outstanding 26.59M | Public Float 22.06M |
| Beta 0.89 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.92 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 482.19K |
INMB Performance
| 1 Week | 4.96% | ||
| 1 Month | -4.51% | ||
| 3 Months | -14.77% | ||
| 1 Year | -82.79% | ||
| 5 Years | -89.21% |
INMB Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
About inmune bio inc - INMB
INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.
INMB At a Glance
INmune Bio, Inc.
225 NE Mizner Boulevard
Boca Raton, Florida 33432
| Phone | 1-858-964-3720 | Revenue | 50.00K | |
| Industry | Biotechnology | Net Income | -45,933,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 257.143% | |
| Fiscal Year-end | 12 / 2026 | Employees | 21 | |
| View SEC Filings |
INMB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 772.435 |
| Price to Book Ratio | 1.763 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.484 |
| Enterprise Value to Sales | 298.095 |
| Total Debt to Enterprise Value | 0.069 |
INMB Efficiency
| Revenue/Employee | 2,380.952 |
| Income Per Employee | -2,187,285.714 |
| Receivables Turnover | 0.011 |
| Total Asset Turnover | 0.001 |
INMB Liquidity
| Current Ratio | 3.551 |
| Quick Ratio | 3.551 |
| Cash Ratio | 2.941 |
INMB Profitability
| Gross Margin | -68.00 |
| Operating Margin | -61,738.00 |
| Pretax Margin | -91,866.00 |
| Net Margin | -91,866.00 |
| Return on Assets | -127.746 |
| Return on Equity | -165.164 |
| Return on Total Capital | -187.039 |
| Return on Invested Capital | -163.242 |
INMB Capital Structure
| Total Debt to Total Equity | 4.396 |
| Total Debt to Total Capital | 4.21 |
| Total Debt to Total Assets | 3.196 |
| Long-Term Debt to Equity | 1.747 |
| Long-Term Debt to Total Capital | 1.674 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Inmune Bio Inc - INMB
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 374.00K | 155.00K | 14.00K | 50.00K | |
Sales Growth
| +106.63% | -58.56% | -90.97% | +257.14% | |
Cost of Goods Sold (COGS) incl D&A
| - | - | - | 84.00K | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | - | - | 84.00K | - |
Depreciation
| - | - | - | 84.00K | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | - | - | - |
Gross Income
| - | - | - | (34.00K) | - |
Gross Income Growth
| - | - | - | - | - |
Gross Profit Margin
| - | - | - | -68.00% | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 26.32M | 29.90M | 42.65M | 30.84M | |
Research & Development
| 17.07M | 20.27M | 33.17M | 20.66M | |
Other SG&A
| 9.26M | 9.62M | 9.48M | 10.18M | |
SGA Growth
| -10.26% | +13.57% | +42.66% | -27.70% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 15.91M | - |
EBIT after Unusual Expense
| (25.95M) | (29.74M) | (42.63M) | (46.78M) | |
Non Operating Income/Expense
| (1.35M) | (267.00K) | 553.00K | 850.00K | |
Non-Operating Interest Income
| - | - | - | 850.00K | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (27.30M) | (30.01M) | (42.08M) | (45.93M) | |
Pretax Income Growth
| +10.02% | -9.92% | -40.24% | -9.15% | |
Pretax Margin
| -7,299.20% | -19,360.00% | -300,585.71% | -91,866.00% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (27.30M) | (30.01M) | (42.08M) | (45.93M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (27.30M) | (30.01M) | (42.08M) | (45.93M) | |
Net Income Growth
| +10.02% | -9.92% | -40.24% | -9.15% | |
Net Margin Growth
| -7,299.20% | -19,360.00% | -300,585.71% | -91,866.00% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (27.30M) | (30.01M) | (42.08M) | (45.93M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (27.30M) | (30.01M) | (42.08M) | (45.93M) | |
EPS (Basic)
| -1.5228 | -1.6689 | -2.11 | -1.8553 | |
EPS (Basic) Growth
| +19.04% | -9.59% | -26.43% | +12.07% | |
Basic Shares Outstanding
| 17.93M | 17.98M | 19.94M | 24.76M | |
EPS (Diluted)
| -1.5228 | -1.6689 | -2.11 | -1.8553 | |
EPS (Diluted) Growth
| +19.04% | -9.59% | -26.43% | +12.07% | |
Diluted Shares Outstanding
| 17.93M | 17.98M | 19.94M | 24.76M | |
EBITDA
| (25.95M) | (29.74M) | (42.63M) | (30.79M) | |
EBITDA Growth
| +10.98% | -14.60% | -43.35% | +27.79% | |
EBITDA Margin
| -6,938.77% | -19,187.74% | -304,535.71% | -61,570.00% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 7.00 | |
| Number of Ratings | 4 | Current Quarters Estimate | -0.215 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -0.773 | |
| Last Quarter’s Earnings | -0.22 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.86 | Next Fiscal Year Estimate | -0.717 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 4 | 3 |
| Mean Estimate | -0.22 | -0.20 | -0.77 | -0.72 |
| High Estimates | -0.13 | -0.12 | -0.55 | -0.51 |
| Low Estimate | -0.29 | -0.28 | -1.05 | -1.09 |
| Coefficient of Variance | -32.56 | -34.88 | -26.87 | -45.20 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 3 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Overweight |
SEC Filings for Inmune Bio Inc - INMB
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Inmune Bio Inc - INMB
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Cory Ellspermann Interim CFO | 30,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Scott Juda Director | 15,975 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Scott Juda Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Scott Juda Director | 108,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Scott Juda Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Scott Juda Director | 108,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Scott Juda Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | 12,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | 32,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | 35,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | 35,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | 19,025 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | 15,975 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Marcia Allen Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |